November 16, 2016 - By Linda Rogers · 0 Comments
The stock of SOLIGENIX INCORPORATED (OTCMKTS:SNGX) registered an increase of 0.54% in short interest. SNGX’s total short interest was 389,600 shares in November as published by FINRA. Its up 0.54% from 387,500 shares, reported previously. With 157,800 shares average volume, it will take short sellers 3 days to cover their SNGX’s short positions. The stock last traded at $3.11 per share. It is down 13.79% since March 4, 2016 and is downtrending. It has underperformed by 18.48% the S&P500.
Soligenix, Inc. (Soligenix), incorporated on January 16, 1987, is a late-stage biopharmaceutical company. The Firm is focused on developing and commercializing products to treat rare diseases. The Firm operates through two divisions: BioTherapeutics and Vaccines/BioDefense. The Company’s BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn’s disease (SGX203) and acute radiation enteritis (SGX201), and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer. The Company’s Vaccines/BioDefense business segment includes active development programs for RiVax, its ricin toxin vaccine candidate, OrbeShield, its GI acute radiation syndrome (GI ARS) therapeutic candidate, and SGX943, its melioidosis therapeutic candidate. The development of its vaccine programs is supported by heat stabilization technology, known as ThermoVax.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Linda Rogers